Clinical trial · Observational
Pediatrics HOT COVID-19 Database in NY Tristate
Retrospective and Prospective Database of COVID-19 Prevalence and Clinical Course in Pediatric and Young Adult Hematology/ Oncology/Stem Cell Therapy Patients in the New York Tri-State Area.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
New York City (NYC) has become the epicenter of the worldwide pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). By collecting and summarizing the experience with other major health care providers in the tristate (New York (NY), New Jersey (NJ) and Connecticut (CT)) are, the investigators are uniquely positioned to inform the rest of the country about what to expect and how to manage children and young adults with hematological, oncological or stem cell transplant diagnoses during the pandemic.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| COVID-19 | — | UNRESOLVED | — |
| Hemoglobinopathies | — | UNRESOLVED | — |
| Immune System Disorder | — | UNRESOLVED | — |
| Pediatric Cancer | Childhood Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (5)
- label
- Heme/Non-Sickle Cell Disease
- description
- Subjects with a diagnosis of hemoglobinapathy except Sickle Cell Disease
- label
- Heme/Sickle Cell Disease
- description
- Subjects with a diagnosis of Sickle Cell Disease
- label
- Neuro-Oncological Disease
- description
- Oncology diagnosis with involvement of the neurological system
- label
- Oncology/Non-Neuro-Oncological
- description
- Subjects with any oncology diagnosis except those that involve the neurological system.
- label
- Transplant patients
- description
- Subjects who have received or are intending to have a stem cell transplant for treatment of disease.
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Hematologic, Oncologic or Stem Cell Transplant Diagnosis * Tested for COVID-19 * Age up to 21 years of age Exclusion Criteria: * Unwillingness to participate
References
Publications (0)
Data not yet available